Michael Gelband’s Ocular Therapeutix OCUL Stock Holding History

Michael Gelband’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$508K	Buy	+51,730	New	+$469K	﹤0.01%	1239
2025 Q4	–	Sell	-163,132	Closed	-$1.91M	–	1916
2025 Q3	$1.91M	Buy	+163,132	New	+$1.95M	0.02%	747
2025 Q2	–	Sell	-96,185	Closed	-$705K	–	1838
2025 Q1	$705K	Buy	+96,185	New	+$739K	0.01%	1018
2023 Q4	–	Sell	-98,422	Closed	-$309K	–	1884
2023 Q3	$309K	Buy	+98,422	New	+$403K	﹤0.01%	1413
2022 Q4	–	Sell	-13,402	Closed	-$56K	–	1982
2022 Q3	$56K	Buy	+13,402	New	+$67.5K	﹤0.01%	1791
2022 Q2	–	Sell	-11,306	Closed	-$56K	–	2292
2022 Q1	$56K	Buy	+11,306	New	+$62.7K	﹤0.01%	2054
2021 Q4	–	Sell	-13,662	Closed	-$137K	–	2476
2021 Q3	$137K	Buy	13,662 +3,561	+35%	+$40K	﹤0.01%	1856
2021 Q2	$143K	Buy	+10,101	New	+$154K	﹤0.01%	2071

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's OCUL Position: Q2 2026 in Review

Michael Gelband opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 51,730 shares worth $508K. The stake represents ﹤0.01% of the portfolio and ranks #1239 among its holdings. This is a return to the name: Michael Gelband previously reported a position in OCUL as recently as Q3 2025.

Michael Gelband first reported a position in OCUL in Q2 2021 and has held it in 8 quarters since. The position peaked at $1.91M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Michael Gelband held 51,730 shares of Ocular Therapeutix worth $508K as of Q2 2026.
Ocular Therapeutix was a new Michael Gelband position in Q2 2026.
Ocular Therapeutix made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1239 holding.
Michael Gelband first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 8 quarters since.
Michael Gelband's Ocular Therapeutix position peaked at $1.91M in Q3 2025.
260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.